Eris Lifesciences has allotted 23,06,372 equity shares related to the acquisition of Swiss Parenterals Limited. The allotment was priced at INR 1835.35 per share. This move finalizes the deal where Eris Lifesciences acquired 16,74,493 equity shares of Swiss Parenterals, representing 30% of its total share capital. Swiss Parenterals is now a wholly-owned subsidiary of Eris Lifesciences.
Acquisition Finalized
Eris Lifesciences has completed the acquisition of Swiss Parenterals Limited, with the allotment of 23,06,372 equity shares. The decision was made during a Board of Directors meeting on January 16, 2026.
Details of Share Allotment
The company allotted 23,06,372 fully paid-up equity shares at a price of INR 1835.35 per share. This includes a premium of INR 1834.35 per equity share. The shares were issued on a preferential basis through private placement.
Swiss Parenterals Acquisition
This allotment is in consideration of Eris Lifesciences’ acquisition of 16,74,493 fully paid-up equity shares of Swiss Parenterals, representing 30% of the company’s total share capital. With this acquisition completed on January 16, 2026, Swiss Parenterals is now a wholly-owned subsidiary of Eris Lifesciences.
Post-Allotment Equity
Following the allotment of new shares, the paid-up equity capital of Eris Lifesciences has increased to INR 13,85,23,263 consisting of 13,85,23,263 equity shares.
Source: BSE
